

1 **Opioid distribution trends in California post recreational marijuana legalization**

2 Michelle N. Anyaehie, MBS¹, Christian Pardo, MBS¹, Elijah J Johnson, MBS¹, Chucks
3 Anachebe MBS¹, Brian J. Piper, PhD^{1,2}

4

5 ¹Geisinger Commonwealth School of Medicine, Scranton, PA 18590

6 ²Center for Pharmacy Innovation and Outcomes, Forty Fort, PA

7

8 525 Pine St, Scranton, PA 18510

9 Correspondence: Michelle N Anyaehie: manyaehie@som.geisinger.edu

10

11 Word count

- 12 ▪ Abstract: 193
- 13 ▪ Manuscript: 2,195
- 14 ▪ Figures: 4
- 15 ▪ Supplemental Figures: 2
- 16 ▪ Tables: 0

17

18

19

20

21

22

23

24

25

26

27

28

29

30 **Abstract**

31 The opioid epidemic has risen to an all-time high. Harm reduction and prevention
32 policies have not alleviated this crisis. Recent investigations have highlighted the
33 efficacy and safety of marijuana-based products for pain management. Providing
34 alternative pain treatment options may help mitigate the opioid epidemic. The
35 distribution of codeine, fentanyl, hydrocodone, morphine, and oxycodone per 100K
36 people and by 3-digit zip codes and overdose rates from 2014 to 2018 in California,
37 which legalized recreational marijuana in 2016, were compared to Texas, where
38 marijuana is functionally prohibited. Drug weights were obtained from the Automation of
39 Reports and Consolidated Orders System and converted to oral morphine milligram
40 equivalents. Overdose data was retrieved from the Centers for Disease Control's
41 WONDER database. California (-43.7%) and Texas (-27.3%) showed significant
42 reductions in cumulative opioid distribution from 2014 to 2018. Opioid distribution per
43 100K people decreased -38.9% in California relative to -26.4% in Texas. Opioid and
44 heroin overdoses increased between 1999 and 2019 by +11.6% in California but
45 +272.7% in Texas. This evidence supports marijuana legalization as a mitigating factor
46 to the opioid epidemic. Continued studies on safer pain management alternatives and
47 policies will help identify measures that help combat the opioid epidemic.

48
49

50

51 **Key words:** Marijuana, cannabis, opioid epidemic, medical marijuana, opioids, pain
52 management

53 **Introduction**

54 The opioid epidemic is characterized by a steep increase in opioid prescription
55 rates followed by a rise in opioid-related deaths in the early 1990s. Opioid prescriptions
56 quadrupled from 1998 to 2008 and resulted in alarming overdose rates (Jones et al.,
57 2018). Nationwide opioid prescription rates steadily increased from 2006 to 2012 but
58 started decreasing from 2013 to 2018 (CDC Injury Center, 2020), showing there has
59 been an effort to alleviate the crisis. Removing pain as the fifth vital sign, implementing
60 drug disposal programs, and returning unused medications are several measures that
61 have been enacted (Cabrera et al., 2019). However, these measures have had little to
62 no effect on opioid distribution and control of opioid-related deaths. In fact, there were
63 approximately 65,000 deaths in 2016, an increase of 21% from the year prior (Jones et
64 al., 2018). California reported six opioid related deaths per 100K people in 2018 (NIDA,
65 2020). Comparably, Texas reported five opioid related deaths per 100K people in 2018
66 (NIDA, 2020). The opioid prescription rate was 35.1 prescriptions per 100 persons in
67 California (Huey & Apollonio, 2019) and 47.2 in Texas (NIDA, 2020) in 2018.

68 Due to stringent federal legislature, there has been little research deciphering the
69 effects of medical marijuana, particularly using products available at dispensaries, and
70 therefore the relationship between marijuana use and trends in opioid distribution and
71 narcotic overdoses has not been fully elucidated. However, California legalized
72 medicinal marijuana in 1996 and recreational marijuana in 2016. Recreational
73 dispensaries opened to individuals who were at least 21 years of age in January 2018.
74 As data demonstrating marijuana's success as an alternative to opioids is presented
75 (Blake et al., 2019; Boehnke et al., 2016; Kienzl et al., 2020; Lee et al., 2018; Sagy et
76 al., 2019; Ware et al., 2015), resulting opioid trends can be analyzed. In this study,
77 opioid distribution rates in California, where medical marijuana and recreational
78 marijuana use was legalized, by zip code and per capita, were compared to Texas,
79 which has not legalized recreational or medical marijuana. Texas caps the percent
80 tetrahydrocannabinol at 0.5% and enrollment (3,519 in Dec, 2020) in their program
81 relative to state's population is modest (Sparber & Jones, 2021). We hypothesize that
82 there will be a greater decrease in opioid distribution in California following the change
83 in marijuana legislation than in Texas.

84 **Methods**

85 **Procedure**

86 The Drug Enforcement Administration's Automation of Reports and Consolidated
87 Orders System (ARCOS) Database is used to track controlled substances from
88 manufacture, through distribution channels to point-of sale at the level of hospitals,
89 pharmacies, practitioners, and teaching institutions. The data is organized in several
90 reports summarizing drug distribution by first three-digits of the zip code, per 100K
91 population gathered and includes summaries of purchases. Report 1, which reports
92 drug distribution by zip code, and Report 3, which reports quarterly drug distribution by
93 state per 100,000 population by gram were selected for analysis (*ARCOS Retail Drug
94 Summary Report - 2011 Reporting Period*, n.d.; Ighodaro et al., 2019). Fentanyl,
95 oxycodone, morphine, hydrocodone and codeine were chosen based on their familiarity
96 in the general population and inclusion in prior research (Cabrerria et al., 2018; Ighodaro
97 et al., 2019; Piper et al., 2017). ARCOS data has been previously validated by
98 comparing results to a state Prescription Drug Monitoring Program which showed a
99 satisfactory ($r = 0.985$) agreement (Piper et al., 2017).

100 The Center for Disease Control WONDER database was constructed to facilitate
101 access to public health information for state and local health departments and the
102 academic public health community (Friede et al., 1994). The mortality data was
103 extracted from WONDER as "Drug-induced causes" set as the underlying cause of
104 death with the Multiple Cause of Death ICD-10 codes T40.1- "Heroin" and T40.2- "Other
105 opioids". ICD-10 code T40.1 is limited to heroin induced deaths. ICD-10 code T40.2
106 excludes non-opioid narcotics, such as cocaine, opium, and LSD, and may include but
107 is not limited to codeine, fentanyl, hydrocodone, hydromorphone, morphine, oxycodone,
108 and tramadol. Total overdose rate includes heroin and other opioid induced deaths.

109 **Data Analysis**


110 The weights of five common opioids (codeine, fentanyl, hydrocodone, morphine,
111 and oxycodone) were converted to oral Morphine Milligram Equivalents (MME) (Piper et
112 al., 2018). Outliers were tested for using Grubbs' Test on GraphPad Prism. Oxycodone
113 distribution per zip code was unavailable in ARCOS for the year 2018. To account for
114 this, oxycodone distribution in the last two quarters of 2017 was average with
115 oxycodone distribution in the first two quarters of 2019 to represent oxycodone
116 distribution in 2018. Heat maps and graphs were constructed using Microsoft Excel and
117 GraphPad Prism 8. Two-tailed paired equal variance t-tests were performed using
118 GraphPad Prism 8 software on zip code distribution data to determine statistical
119 differences with $p < 0.05$ considered significant.

120 **Results**

121 **Opioid Distribution by Zip Code**


122 In both 2014 and 2018, California showed much more widespread and
123 substantial cumulative opioid distribution as seen in Fig. 1(A-B). In 2014, portions of
124 California surrounding the Bay Area and portions of Southern California had cumulative
125 opioid distributions as high as 1,388,000 MME and 900,000 MME, respectively. In
126 contrast, the highest distribution in Texas was 790,000 MME in the surrounding Dallas
127 area. Most of Texas had a distribution of 100,000 or less while most zip codes in
128 California ranged from 150,000 to 650,000 (Fig. 1A). However, in 2018, the largest
129 distributions in California dropped to 720,000 MME in the Bay Area and 525,000 MME
130 in Southern California, decreases of 50 and 40 percent respectively (Fig. 1B). The
131 surrounding Dallas area saw a decrease of 25 percent while most of Texas did not
132 show a comparable decrease (Fig. 1C). Both California ($p < 0.0001$) and Texas
133 ($p < 0.0001$) showed statistically significant decreases in opioid distribution, but California
134 had an over two-fold difference per zip code (162,476 versus 62,808 MME) over this
135 five-year span. This represents a -43.7% decrease in California relative to only -27.3%
136 in Texas (Fig. 2). There was an increase of 6,000 MME in a 16-zip code area of
137 Southern California near Glendale and Burbank. In this area, fentanyl, morphine, and
138 oxycodone saw 1.5, 2.4, and 1.8-fold increases respectively while codeine and
139 hydrocodone did not undergo appreciable changes (Fig. 1C).

140




141

142




143

144



145 **Figure 1.** Total opioid distribution in California and Texas in Morphine Mg Equivalents
146 (MME) by zip code as reported to the Drug Enforcement Administrations Automation of
147 Reports and Consolidated Ordering System in 2014 **(A)** and 2018 **(B)**. Percent change
148 from 2014 to 2018 **(C)**.

149



150


151 **Figure 2.** Opioid distribution (\pm SEM) per zip code as reported by the Drug Enforcement
152 Administration's Automation of Reports and Consolidated Orders System. Morphine Mg
153 Equivalent: MME. * $p < .05$ versus 2014.

154

155 Opioid Distribution Per Capita

156 Opioid distribution per capita decreased in both California and Texas from 2014
157 to 2018 (-38.9% and -26.4% respectively). The change in California was more linear for
158 all opioids while Texas experienced more variable change (Fig. 3). Distribution of all five
159 opioids in California decreased to a greater extent than their Texan counterparts
160 (hydrocodone -65.4%, fentanyl -50.3%, morphine -42.7%, oxycodone -32.4%, and
161 codeine -19.1%, Fig. 3). Individual opioid distribution changes in Texas showed much
162 more variability with hydrocodone, fentanyl, and morphine distribution decreasing (-
163 42.3%, -36.7%, and -27.8%), oxycodone remaining essentially unchanged (-0.5%), and
164 codeine distribution increasing 150.1% (Fig. 3).

165




166 **Figure 3.** Per capita distribution of selected opioids from 2014 to 2018 as reported to
167 the Drug Enforcement Administration's Automation of Reports and Consolidated Orders
168 System in California (A) and Texas (B). The percent change from 2014 to 2018 is
169 shown in the key.

170 Overdose rates

171 Overall, opioid related deaths increased in California (11.6%) and Texas
172 (272.7%) between 1999 and 2019. California showed a decline in deaths from non-
173 heroin opioids between 2014-2019 (Fig. 4A) while Texas had an increase in deaths
174 from 2014-2017 and then experienced a decline in 2018 (Fig. 4B). Heroin related
175 deaths have increased continuously in California (71.4%) and Texas (400%) between
176 1999 and 2019.

177



178 **Figure 4.** Opioid overdose rates as reported by the CDC's Wide Ranging Online Data
179 for Epidemiologic Research (WONDER) from 1999 to 2019 in California (A) and Texas
180 (B). The percent change from 1999 to 2019 is listed in the key.

181

182 Discussion

183 The observed trends in opioid distribution by zip code and per capita in California
184 and Texas support recreational marijuana legalization as a practical measure to help
185 reduce prescription opioid use. The five years analyzed (2014 – 2018) show a greater
186 decrease in California than in Texas (Fig. 2). Opioid distribution per 100K people in
187 California decreased 38.9% from 2014-2018 while distribution in Texas decreased by
188 only 26.4% (Fig. 3). Similarly, heat map analysis (Fig. 1(A-B)) illustrates a greater
189 decrease in opioid distribution over large areas of California compared to Texas from
190 2014 to 2018. These findings are consistent with investigations showing fewer opioid
191 prescriptions written in states where medical marijuana laws are passed (Bradford &
192 Bradford, 2016). A similar study showed a significant correlation between increased
193 marijuana use as a treatment for chronic pain and reduced opioid use (Boehnke et al.,
194 2016), suggesting a potential public health benefit of replacing opioids with cannabis.

195 The drop in hydrocodone and increase in codeine and oxycodone distribution per
196 capita seen in Texas (Fig. 3) is consistent with previous data showing that oxycodone
197 and codeine increased by weight distribution from 2014 to 2017 specifically in Texas
198 (NIDA, 2020). The reclassification of hydrocodone in 2014 from a schedule III to a
199 schedule II may be a factor behind this trend (Bohnert et al., 2018; NIDA, 2020).
200 Increased restrictions surrounding hydrocodone may have created an environment for
201 the distribution of oxycodone and codeine to rise as there were fewer powerful
202 analgesic options available, such as cannabis products.

203 The decreasing trends observed in California (Fig.3) may be explained by current
204 approaches to treating pain and the reduction in opioid use as a result of medicinal and
205 recreational marijuana legalization. Three-fifths (62%) of women surveyed in California
206 and Colorado with gynecological malignancies stated their interest in non-prescription
207 cannabis and 35.6% were interested in using cannabis under the guidance of
208 physicians. One-quarter (26.7%) of these patients reported already using non-
209 prescription cannabis products to manage various cancer related symptoms (Blake et
210 al., 2019).

211 California saw a decrease in overdose deaths after the legalization of marijuana
212 in 2016 and 2018 (Fig.4), whereas Texas, which has not legalized marijuana,
213 experienced a rise in deaths by overdose in 2016 and 2017 however a gradual
214 decrease in 2018 was also shown. Results from our data could be accounted for by the
215 implementation of laws across the U.S. designed to mitigate overdoses by limiting
216 opioid prescriptions and institutionalizing Prescription Drug Monitoring Programs
217 introduced in 2017 (McGinty et al., 2018). Prior research has found that any association
218 between medical marijuana and opioid overdoses is complicated (Bachhuber et al.,
219 2014; Kaufman et al., 2021; Shover et al., 2019), but further studies will help describe
220 the relationship between changing marijuana legislature and opioid overdoses.

221 Although harm reduction policies and medication-assisted treatments for opioid
222 dependence have increased in availability, (e.g. sterile syringe access programs and
223 methadone) (Bohnert et al., 2018), alternative pain management strategies must be
224 employed to decrease access and use of opioids to lower addiction and overdose rates.
225 States that enacted medical cannabis laws had a 24.8% reduction in opioid overdose
226 mortality which further decreased in the years following their implementation
227 (Bachhuber et al., 2014). Evidence supports the promotion of safer and less addictive
228 alternatives for analgesic relief, and implementation of laws that could reduce the
229 misuse and abuse of opioids.

230 There were a variety of limitations to our study. Limited research on recreational
231 and non-prescription marijuana for analgesic effects makes it difficult to make accurate
232 analysis and inferences. Most findings on cannabis and chronic pain refer to medical
233 cannabis, but patients have reported using recreational and non-prescription cannabis
234 for medical benefits (Blake et al., 2019). Surveys taken to assess the use of recreational
235 and non-prescription marijuana from dispensaries would help differentiate between
236 recreational and medicinal marijuana use. The data extracted from ARCOS presented a
237 further limitation as the census data used by the Drug Enforcement Administration is
238 from 2010. Including more control states and utilizing 2020 census data, when
239 available, might be beneficial in future studies (Andreae et al., 2016). In addition,
240 ARCOS does not account for mail-order pharmacies and internet pharmacies that ship
241 different prescription opioids across state lines, including the five opioids used in this
242 study (NIDA, 2020). Lastly, statistics gathered from CDC WONDER database do not
243 provide specific details on overdose outcomes and includes overdoses from all opioids,
244 not just the five previously discussed. Overdose data from WONDER may also be
245 underestimated and accuracy varies from state to state as there is no standardized
246 national reporting practice (NIDA, 2020; NIDA, 2020; Kaufman et al., 2021). However,

247 both California and Texas were rated by the CDC as in the same “less than good”
248 category for death determination quality (Kaufman et al., 2021).

249 **Conclusion**

250 Prescription opioid distribution in California showed a greater decrease
251 compared to Texas (43.7% and 27.3% respectively). These findings suggest a
252 relationship between California’s marijuana legislation and the decreased opioid
253 distribution when compared to a state that has legislation prohibiting medicinal or
254 recreational marijuana use. As more states increase access to cannabis, trends in
255 opioid distribution and use, as well as opioid overdoses, must be further analyzed to
256 promote legislature to help combat the opioid epidemic.

257 **Author Contributions**

258 Michelle N Anyaehie conceived and designed the study, performed literature search
259 and review, authored drafts of the paper, analyzed the data and approved the final
260 manuscript.

261 Christian Pardo conceived and designed the study, performed literature search and
262 review, analyzed the data, prepared figures, authored drafts of the paper, and approved
263 the final manuscript.

264 Elijah J Johnson conceived and designed the study, performed literature search and
265 review, authored drafts of the paper, and approved the final manuscript.

266 Chucks Anachebe authored drafts of the paper and approved the final manuscript.

267 Dr. Brian Piper authored drafts of the paper, analyzed data, and approved the final
268 manuscript.

269 **Conflicts of Interest**

270 The authors do not report any conflicts of interest.

271 **Acknowledgments**

272 We would like to thank Elizabeth Kuchinski, MPH and Dan Kaufman, MBS at Geisinger
273 Commonwealth School of Medicine for their guidance and feedback throughout this
274 study.

275

276 **References**

277 Andrae, M. H., Rhodes, E., Bourgoise, T., Carter, G. M., White, R. S., Indyk, D.,
278 Sacks, H., & Rhodes, R. (2016). An Ethical Exploration of Barriers to Research on
279 Controlled Drugs. *American Journal of Bioethics*, 16(4), 36–47.
280 <https://doi.org/10.1080/15265161.2016.1145282>

281 ARCOS Retail Drug Summary Report. (2020). *2011 Reporting Period*. Retrieved
282 January 27, 2021, from
283 https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/2011/index.html

284 Bachhuber, M. A., Saloner, B., Cunningham, C. O., & Barry, C. L. (2014). Medical
285 cannabis laws and opioid analgesic overdose mortality in the United States, 1999-
286 2010. *JAMA Internal Medicine*, 174(10), 1668–1673.
287 <https://doi.org/10.1001/jamainternmed.2014.4005>

- 288 Blake, E. A., Ross, M., Ihenacho, U., Figueroa, L., Silverstein, E., Flink, D., Mendez-
289 Ishizaki, Y., Yessaian, A., Brunette, L. L., Matsuo, K., Cortessis, V. K., Guntupalli,
290 S., & Roman, L. (2019). Non-prescription cannabis use for symptom management
291 amongst women with gynecologic malignancies. *Gynecologic Oncology Reports*,
292 30. <https://doi.org/10.1016/j.gore.2019.100497>
- 293 Boehnke, K. F., Litinas, E., & Clauw, D. J. (2016). Medical cannabis use is associated
294 with decreased opiate medication use in a retrospective cross-sectional survey of
295 patients with chronic pain. *Journal of Pain*, 17(6), 739–744.
296 <https://doi.org/10.1016/j.jpain.2016.03.002>
- 297 Bohnert, A. S. B., Guy, G. P., & Losby, J. L. (2018). Opioid prescribing in the United
298 States before and after the Centers for Disease Control and Prevention's 2016
299 opioid guideline. *Annals of Internal Medicine*, 169(6), 367–375.
300 <https://doi.org/10.7326/M18-1243>
- 301 Bradford, A. C., & Bradford, W. D. (2016). Medical marijuana laws reduce prescription
302 medication use in medicare part d. *Health Affairs*, 35(7), 1230–1236.
303 <https://doi.org/10.1377/hlthaff.2015.1661>
- 304 Cabrera, F. F., Gamarra, E. R., Garcia, T. E., Littlejohn, A. D., Chinga, P. A., Pinentel-
305 Morillo, L. D., Tirado, J. R., Chung, D. Y., Pande, L. J., McCall, K. L., Nichols, S. D.,
306 & Piper, B. J. (2019). Opioid distribution trends (2006–2017) in the US territories.
307 *PeerJ*, 7, e6272. <https://doi.org/10.7717/peerj.6272>
- 308 CDC Injury Center. (2020). *U.S. Opioid Dispensing Rate Maps | Drug Overdose*.
309 Retrieved from <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html>
- 310 Friede, A., Rosen, D. H., & Reid, J. A. (1994). CDC WONDER: A cooperative
311 processing architecture for public health. *Journal of the American Medical*
312 *Informatics Association*, 1(4), 303–312.
313 <https://doi.org/10.1136/jamia.1994.95236162>
- 314 Huey, J., & Apollonio, D. E. (2019). Review of Tobacco Policies on University of
315 California Campuses. *Californian Journal of Health Promotion*, 17(1), 24–30.
316 <https://doi.org/10.32398/cjhp.v17i1.2221>
- 317 Ighodaro, E. O., McCall, K. L., Chung, D. Y., Nichols, S. D., & Piper, B. J. (2019).
318 Dynamic changes in prescription opioids from 2006 to 2017 in Texas. *PeerJ*,
319 2019(12), 1–14. <https://doi.org/10.7717/peerj.8108>
- 320 Jones, G. H., Bruera, E., Abdi, S., & Kantarjian, H. M. (2018). The opioid epidemic in
321 the United States-Overview, origins, and potential solutions. *Cancer*, 124(22),
322 4279–4286. <https://doi.org/10.1002/cncr.31713>
- 323 Kaufman, D. E., Nihal, A. M., Leppo, J. D., Staples, K. M., McCall, K. L., & Piper, B. J.
324 (2021). Opioid mortality following medical marijuana implementation in the United
325 States. *Pharmacopsychiatry*. 54: 1-5. In press.
- 326 Kienzl, M., Storr, M., & Schicho, R. (2020). Cannabinoids and opioids in the treatment of
327 Inflammatory bowel diseases. In *Clinical and translational gastroenterology*, 11 (1).
328 <https://doi.org/10.14309/ctg.0000000000000120>
- 329 Lee, G., Grovey, B., Furnish, T., & Wallace, M. (2018). Medical cannabis for
330 neuropathic pain. *Current pain and headache reports* (Vol. 22, Issue 1).
331 <https://doi.org/10.1007/s11916-018-0658-8>
- 332 McGinty, E. E., Barry, C. L., Stone, E. M., Niederdeppe, J., Kennedy-Hendricks, A.,

333 Linden, S., & Sherman, S. G. (2018). Public support for safe consumption sites and
334 syringe services programs to combat the opioid epidemic. *Preventive Medicine*,
335 111, 73–77. <https://doi.org/10.1016/j.ypmed.2018.02.026>

336 National Institute on Drug Abuse. (2020). *California: Opioid-Involved Deaths and*
337 *Related Harms*. Retrieved from [https://www.drugabuse.gov/drug-](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state)
338 [topics/opioids/opioid-summaries-by-state](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state)

339 National Institute on Drug Abuse. (2020). *Texas: Opioid-Involved Deaths and Related*
340 *Harms*. Retrieved from [https://www.drugabuse.gov/drug-topics/opioids/opioid-](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state)
341 [summaries-by-state](https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state)

342 Piper, B. J., Shah, D. T., Simoyan, O. M., McCall, K. L., & Nichols, S. D. (2018). Trends
343 in medical use of opioids in the U.S., 2006–2016. *American Journal of Preventive*
344 *Medicine*, 54(5), 652–660. <https://doi.org/10.1016/j.amepre.2018.01.034>

345 Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019). Safety and
346 Efficacy of Medical Cannabis in Fibromyalgia. *Journal of Clinical Medicine*, 8(6),
347 807. <https://doi.org/10.3390/jcm8060807>

348 Shover, C. L., Davis, C. S., Gordon, S. C., & Humphreys, K. (2019). Association
349 between medical cannabis laws and opioid overdose mortality has reversed over
350 time. *Proceedings of the National Academy of Sciences of the United States of*
351 *America*, 116(26), 12624–12626. <https://doi.org/10.1073/pnas.1903434116>

352 Sparber, S., Jones, A. (2020). Texas' medical marijuana program is one of the most
353 restrictive in the country. Advocates hope the Legislature will change that. *Texas*
354 *Tribune*. Accessed 2/20/2021 at: [https://www.texastribune.org/2021/01/04/texas-](https://www.texastribune.org/2021/01/04/texas-medical-marijuana-2021/)
355 [medical-marijuana-2021/](https://www.texastribune.org/2021/01/04/texas-medical-marijuana-2021/)

356 Ware, M. A., Wang, T., Shapiro, S., & Collet, J. P. (2015). Cannabis for the
357 management of pain: Assessment of safety study (COMPASS). *The Journal of*
358 *Pain*, 16(12), 1233–1242. <https://doi.org/10.1016/j.jpain.2015.07.014>

359

360

361

362

363

364

365

366

367

368

369

370


371

372

373


374

375 **Supplemental Figures**



376

377 **Figure S1.** Cumulative change in opioid distribution as reported to the Drug
378 Enforcement Administration's Automation of Reports and Consolidated Orders System
379 in California and Texas from 2014 to 2018.



380
381 **Figure S2.** Opioid composition as reported to the Drug Enforcement Administration's
382 Automation of Reports and Consolidated Orders System per state (California : CA,
383 Texas: TX) in 2014 (top) and 2018 (bottom).